Drug Profile

Olea pollen allergy immunotherapy - Laboratorios LETI

Latest Information Update: 04 May 2015

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Laboratorios LETI
Class Allergens; Antiallergics; Tree pollen allergy immunotherapies
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Seasonal allergic rhinitis

Most Recent Events

31 Jan 2013 Laboratorios Leti completes the phase III OLEA trial in Seasonal allergic rhinitis in Spain (NCT00831025)
16 Oct 2012 Phase-III development is ongoing in Spain
10 Aug 2011 Laboratorios Leti completes enrolment in its phase III trial for Seasonal allergic rhinitis in Spain (NCT00831025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com